Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
University of Hong Kong · Johannes Gutenberg University Mainz · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
233
total citations
- FWCI
- 223.28
- Percentile
- 100%
- References
- 25
Citations per year
Authors
28- TYThomas YauCorresponding
University of Hong Kong
- PRPeter R. Galle
Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz
- TDThomas Decaens
Centre National de la Recherche Scientifique, Inserm, Centre Hospitalier Universitaire de Grenoble, Université Grenoble Alpes
- BSBruno Sangro
Clinica Universidad de Navarra
- SQShukui Qin
China Pharmaceutical University
Topics & keywords
Topics
Keywords
- Lenvatinib
- Sorafenib
- Nivolumab
- Medicine
- Ipilimumab
- Hepatocellular carcinoma
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.